July 15, 2010

Ligand Launches New Corporate Web Site

SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the launch of its completely redesigned Web site: www.ligand.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about Ligand's business model, robust pipeline, high-profile partnerships and innovative technology.

"Our significant developments in the past three years, including restructured operations, multiple acquisitions and drug approvals, have broadened and deepened the Ligand story. This new site provides visitors an architecture that facilitates quick and efficient access to the information they need," said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.

Forward-Looking Statements

This news release contains certain forward-looking statements by Ligand, including statements regarding the development of financial strategies and controls necessary for future growth, which involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Actual events or results may differ from Ligand's expectations. For example, we may not be able to timely or successfully transform the Company or advance any product(s) in our pipeline. In addition, we may not be able to successfully implement our strategy, and continue the development of our proprietary programs. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via the Company's web site, www.ligand.com, as well as in Ligand's public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Source: Ligand Pharmaceuticals Incorporated